Wolfe Research Estimates Biogen’s Q4 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Wolfe Research dropped their Q4 2025 earnings estimates for Biogen in a research note issued on Wednesday, August 6th. Wolfe Research analyst A. Hammond now expects that the biotechnology company will post earnings per share of $3.27 for the quarter, down from their prior forecast of $3.57. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The company had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.32 billion. During the same period last year, the firm posted $5.28 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. HSBC lowered Biogen from a “buy” rating to a “hold” rating and set a $118.00 price target on the stock. in a report on Monday, April 28th. Citigroup boosted their price target on Biogen from $125.00 to $135.00 and gave the company a “neutral” rating in a report on Friday, August 1st. Robert W. Baird cut their price target on Biogen from $300.00 to $255.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Finally, Oppenheimer set a $205.00 price target on Biogen in a report on Friday, May 2nd. Twenty-one investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and an average price target of $185.63.

Biogen Price Performance

NASDAQ BIIB opened at $128.00 on Monday. The business has a 50 day simple moving average of $129.92 and a 200 day simple moving average of $131.17. Biogen has a 52-week low of $110.04 and a 52-week high of $207.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. The stock has a market cap of $18.77 billion, a price-to-earnings ratio of 12.24, a PEG ratio of 1.03 and a beta of 0.13.

Insider Buying and Selling

In related news, insider Rachid Izzar sold 2,223 shares of the company’s stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider owned 6,330 shares in the company, valued at approximately $854,550. This represents a 25.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Biogen by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock valued at $2,171,533,000 after purchasing an additional 257,812 shares during the period. Geode Capital Management LLC boosted its holdings in Biogen by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock valued at $490,089,000 after purchasing an additional 71,286 shares during the period. Invesco Ltd. boosted its holdings in Biogen by 6.4% in the 1st quarter. Invesco Ltd. now owns 2,265,007 shares of the biotechnology company’s stock valued at $309,944,000 after purchasing an additional 136,200 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Biogen by 1.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,933,716 shares of the biotechnology company’s stock valued at $295,705,000 after purchasing an additional 21,170 shares during the period. Finally, Northern Trust Corp boosted its holdings in Biogen by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,550,130 shares of the biotechnology company’s stock valued at $237,046,000 after purchasing an additional 196,995 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.